Natera (NASDAQ:NTRA) Price Target Raised to $157.00 at Craig Hallum

Natera (NASDAQ:NTRA) had its price objective hoisted by Craig Hallum from $121.00 to $157.00 in a research note released on Wednesday morning,Benzinga reports. Craig Hallum currently has a buy rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the company. The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. TD Cowen boosted their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Morgan Stanley boosted their price target on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. boosted their price target on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, BTIG Research boosted their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $135.06.

Natera Stock Performance

Shares of NTRA stock opened at $160.97 on Wednesday. The stock has a fifty day moving average price of $126.04 and a 200 day moving average price of $114.84. The stock has a market cap of $19.91 billion, a PE ratio of -91.46 and a beta of 1.53. Natera has a 1 year low of $49.97 and a 1 year high of $167.79. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.88% and a negative net margin of 14.01%. Natera’s revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.95) earnings per share. Sell-side analysts forecast that Natera will post -1.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $126.45, for a total value of $235,955.70. Following the transaction, the chief financial officer now owns 68,851 shares in the company, valued at approximately $8,706,208.95. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,881 shares of company stock valued at $3,733,983. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Itau Unibanco Holding S.A. acquired a new position in shares of Natera during the second quarter worth about $28,000. Quarry LP lifted its stake in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares in the last quarter. Covestor Ltd lifted its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares in the last quarter. Finally, Brooklyn Investment Group acquired a new position in shares of Natera in the third quarter worth about $70,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.